Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine + lomustine versus lomustine alone in recurrent anaplastic astrocytoma
NL-OMON50263Phase 3Completed
- Sponsor
- Orbus Therapeutics
- Start
- Jan 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eflornithine, lomustine in anaplastic astrocytoma (AA), sponsored by Orbus Therapeutics. Started Jan 2018; status: completed.
02
Drugs
eflornithinelomustine
03
Conditions
anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NL-OMON50263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50263.